The Discounted Cash Flow (DCF) valuation of Bristol-Myers Squibb Co (BMY) is (131.83) USD. With the latest stock price at 49.75 USD, the upside of Bristol-Myers Squibb Co based on DCF is -365.0%.
Based on the latest price of 49.75 USD and our DCF valuation, Bristol-Myers Squibb Co (BMY) is a sell. selling Bmy stocks now will result in a potential gain of 365.0%.
Note: valuation result may not be accurate due to the low predictability of business.
| Range | Selected | |
| WACC / Discount Rate | 5.1% - 6.7% | 5.9% |
| Long-term Growth Rate | 3.0% - 4.8% | 3.9% |
| Fair Price | (879.93) - (81.54) | (131.83) |
| Upside | -1868.7% - -263.9% | -365.0% |